[{"id":"e3849c3a-6be4-415c-bb15-50c8c05581ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190833","created_at":"2025-09-27T08:40:11.891Z","updated_at":"2025-09-27T08:40:11.891Z","phase":"Phase 1","brief_title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)","source_id_and_acronym":"NCT07190833","lead_sponsor":"Bionoxx Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-09-24"},{"id":"d70dbe69-fc0c-4491-b69e-8481a8fc0c63","acronym":"","url":"https://clinicaltrials.gov/study/NCT07170592","created_at":"2025-09-20T07:09:01.411Z","updated_at":"2025-09-20T07:09:01.411Z","phase":"Phase 1","brief_title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","source_id_and_acronym":"NCT07170592","lead_sponsor":"Bionoxx Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • hydroxyurea"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-09-12"},{"id":"9de3eb66-06bd-4d1a-92a9-adae61b8b59a","acronym":"Acclaim-1","url":"https://clinicaltrials.gov/study/NCT04486833","created_at":"2021-01-18T21:32:20.912Z","updated_at":"2025-02-25T12:27:38.683Z","phase":"Phase 1/2","brief_title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","source_id_and_acronym":"NCT04486833 - Acclaim-1","lead_sponsor":"Genprex, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tagrisso (osimertinib) • carboplatin • Reqorsa (quaratusugene ozeplasmid)"],"overall_status":"Recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 09/03/2021","start_date":" 09/03/2021","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-02-24"},{"id":"79725e7c-a938-4a9e-b556-bf960936b158","acronym":"","url":"https://clinicaltrials.gov/study/NCT03618641","created_at":"2021-09-17T01:53:43.496Z","updated_at":"2025-02-25T16:31:32.025Z","phase":"Phase 2","brief_title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","source_id_and_acronym":"NCT03618641","lead_sponsor":"Diwakar Davar","biomarkers":" CD8 • CD4 • SOX10","pipe":"","alterations":" ","tags":["CD8 • CD4 • SOX10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/08/2018","start_date":" 08/08/2018","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-02-07"},{"id":"91617f4c-9c7b-440c-8f75-457b27099289","acronym":"","url":"https://clinicaltrials.gov/study/NCT02802423","created_at":"2021-01-18T13:44:49.074Z","updated_at":"2025-02-25T16:30:52.764Z","phase":"Phase 1/2","brief_title":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","source_id_and_acronym":"NCT02802423","lead_sponsor":"BioLite, Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • ABV-1501"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 08/28/2027","study_completion_date":" 08/28/2027","last_update_posted":"2025-02-07"},{"id":"93546d33-d260-437a-9cd5-b7629d9d588d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708418","created_at":"2023-04-01T19:06:08.459Z","updated_at":"2025-02-25T16:38:10.265Z","phase":"Phase 2","brief_title":"A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma","source_id_and_acronym":"NCT04708418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vidutolimod (CMP-001) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/15/2021","start_date":" 10/15/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-06"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"86f5d623-e383-4b3e-8efb-11c16dbf36fa","acronym":"Catalyst","url":"https://clinicaltrials.gov/study/NCT05383170","created_at":"2023-02-21T18:01:52.866Z","updated_at":"2025-02-25T16:17:43.709Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers","source_id_and_acronym":"NCT05383170 - Catalyst","lead_sponsor":"Cytovation AS","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CY-101"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 09/23/2024","primary_completion_date":" 09/23/2024","study_txt":" Completion: 09/23/2024","study_completion_date":" 09/23/2024","last_update_posted":"2024-09-27"},{"id":"245ed9e1-ca34-4788-8cc3-6546ba073450","acronym":"","url":"https://clinicaltrials.gov/study/NCT06573398","created_at":"2025-02-27T08:15:39.768Z","updated_at":"2025-02-27T08:15:39.768Z","phase":"Phase 2","brief_title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","source_id_and_acronym":"NCT06573398","lead_sponsor":"Ruijin Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":"","alterations":" ","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-08-27"},{"id":"e975dc1c-7e02-40e7-855c-de3886574f07","acronym":"CICILIA","url":"https://clinicaltrials.gov/study/NCT04260529","created_at":"2021-10-14T21:53:05.598Z","updated_at":"2025-02-25T16:09:57.834Z","phase":"Phase 1/2","brief_title":"CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations","source_id_and_acronym":"NCT04260529 - CICILIA","lead_sponsor":"Cytovation AS","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CY-101"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2020","start_date":" 04/30/2020","primary_txt":" Primary completion: 07/05/2024","primary_completion_date":" 07/05/2024","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2024-07-24"},{"id":"6cd3b965-1498-4a7b-8e52-1d5006e1cb85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05322850","created_at":"2022-04-12T14:52:55.429Z","updated_at":"2024-07-02T16:34:26.410Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)","source_id_and_acronym":"NCT05322850","lead_sponsor":"University of Florida","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OrcaGraft (engineered donor allograft cell therapy)"],"overall_status":"Suspended","enrollment":" Enrollment 40","initiation":"Initiation: 08/16/2022","start_date":" 08/16/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-06-13"},{"id":"4bc744c9-f84b-494d-8e5c-dc24132e3743","acronym":"Precision-T (PhIII component)","url":"https://clinicaltrials.gov/study/NCT05316701","created_at":"2022-04-07T12:57:08.884Z","updated_at":"2024-07-02T16:35:00.902Z","phase":"Phase 3","brief_title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT05316701 - Precision-T (PhIII component)","lead_sponsor":"Orca Biosystems, Inc.","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-27"},{"id":"50675b6c-a099-4a04-9217-8bea26cfbfcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06026605","created_at":"2023-09-07T16:09:36.545Z","updated_at":"2024-07-02T16:35:03.844Z","phase":"Phase 1","brief_title":"A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients With Advanced Malignant Tumors","source_id_and_acronym":"NCT06026605","lead_sponsor":"Zhejiang University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WTX212"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 08/25/2023","start_date":" 08/25/2023","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-05-14"},{"id":"bb2676c0-4169-4f0b-8560-87eaebe4bee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06408298","created_at":"2024-05-10T20:31:50.268Z","updated_at":"2024-07-02T16:35:04.490Z","phase":"Phase 1","brief_title":"HCQ in Resectable Localized Prostate Cancer","source_id_and_acronym":"NCT06408298","lead_sponsor":"Lionel.D.Lewis, MD","biomarkers":" BNIP3","pipe":"","alterations":" ","tags":["BNIP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hydroxychloroquine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-05-10"},{"id":"e0dcb469-2253-48cc-bf9a-3c24a50a8266","acronym":"","url":"https://clinicaltrials.gov/study/NCT04401995","created_at":"2022-04-05T20:52:55.878Z","updated_at":"2024-07-02T16:35:06.245Z","phase":"Phase 2","brief_title":"Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab","source_id_and_acronym":"NCT04401995","lead_sponsor":"Diwakar Davar","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • vidutolimod (CMP-001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 07/30/2028","primary_completion_date":" 07/30/2028","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2024-05-03"},{"id":"e93517f6-aee4-46a7-9ae6-62f1d5bba6f6","acronym":"Reboot-105","url":"https://clinicaltrials.gov/study/NCT06106152","created_at":"2024-03-26T18:39:47.230Z","updated_at":"2024-07-02T16:35:12.830Z","phase":"Phase 1","brief_title":"WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody","source_id_and_acronym":"NCT06106152 - Reboot-105","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WTX212"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-26"},{"id":"884c90cc-7b41-4f27-b4c0-809cc02777c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05914376","created_at":"2023-06-22T19:11:48.636Z","updated_at":"2024-07-02T16:35:15.173Z","phase":"Phase 1","brief_title":"Safety of Recombinant Human IL-21 Oncolytic Vaccinia Virus Injection（hV01) in Advanced Tumors","source_id_and_acronym":"NCT05914376","lead_sponsor":"Hangzhou Converd Co., Ltd.","biomarkers":" EGFR • CD8 • IFNG • IL6 • TNFA • CD4 • NCAM1","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • CD8 • IFNG • IL6 • TNFA • CD4 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e hV01"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-03-12"},{"id":"b8db270b-31ec-42b3-ae0d-efec0f07af53","acronym":"CLEVER","url":"https://clinicaltrials.gov/study/NCT03032406","created_at":"2021-01-18T14:55:32.607Z","updated_at":"2024-07-02T16:35:15.139Z","phase":"Phase 2","brief_title":"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","source_id_and_acronym":"NCT03032406 - CLEVER","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER • ALK • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • hydroxychloroquine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/23/2017","start_date":" 01/23/2017","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/23/2025","study_completion_date":" 05/23/2025","last_update_posted":"2024-03-12"},{"id":"3cd29e52-af9d-4ffc-9f57-b8ce426e67cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05661201","created_at":"2022-12-22T15:59:18.931Z","updated_at":"2024-07-02T16:35:15.432Z","phase":"Phase 1","brief_title":"NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors","source_id_and_acronym":"NCT05661201","lead_sponsor":"Georgetown University","biomarkers":" KRAS • ST2","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Nerofe (84AA-API 14AA)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/12/2023","start_date":" 04/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-03-11"},{"id":"236e87b1-3a45-4987-8e83-19ff77105b1b","acronym":"SU-09142011-8407","url":"https://clinicaltrials.gov/study/NCT01660607","created_at":"2021-01-18T07:10:13.721Z","updated_at":"2024-07-02T16:35:17.716Z","phase":"Phase 1/2","brief_title":"Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell","source_id_and_acronym":"NCT01660607 - SU-09142011-8407","lead_sponsor":"Everett Meyer","biomarkers":" FLT3 • HLA-DRB1","pipe":" | ","alterations":" Chr t(9;11)","tags":["FLT3 • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 12/20/2023","study_completion_date":" 12/20/2023","last_update_posted":"2024-02-26"},{"id":"a371a01d-3ae1-4151-8cf6-c3f5a72a47d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507827","created_at":"2022-08-19T17:10:05.391Z","updated_at":"2024-07-02T16:35:18.561Z","phase":"Phase 1","brief_title":"Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT05507827","lead_sponsor":"Dr. Melody Smith, MD, MS","biomarkers":" CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement","tags":["CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T • firicabtagene autoleucel (CRG-022)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 01/01/2037","primary_completion_date":" 01/01/2037","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-02-20"},{"id":"c311b6de-e0a7-45b5-8687-2b4f0b991615","acronym":"BIG","url":"https://clinicaltrials.gov/study/NCT06253611","created_at":"2024-02-12T19:28:04.493Z","updated_at":"2024-07-02T16:35:18.871Z","phase":"Phase 2","brief_title":"First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer","source_id_and_acronym":"NCT06253611 - BIG","lead_sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-02-19"},{"id":"0a2b6a01-05fa-45b9-8f95-563e2bdc18c7","acronym":"NCI-2017-02205","url":"https://clinicaltrials.gov/study/NCT03399773","created_at":"2021-03-30T16:52:36.349Z","updated_at":"2024-07-02T16:35:19.269Z","phase":"Phase 2","brief_title":"Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes","source_id_and_acronym":"NCT03399773 - NCI-2017-02205","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • CD34 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • Omisirge (omidubicel) • cyclophosphamide intravenous • dilanubicel (DVX101)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 10/08/2024","primary_completion_date":" 10/08/2024","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-02-15"},{"id":"c7d821cf-1074-4b09-aa9f-2289017bf8ff","acronym":"CMP-001-007","url":"https://clinicaltrials.gov/study/NCT04633278","created_at":"2021-01-19T20:36:57.016Z","updated_at":"2024-07-02T16:35:21.076Z","phase":"Phase 2","brief_title":"CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04633278 - CMP-001-007","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vidutolimod (CMP-001)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 01/19/2024","primary_completion_date":" 01/19/2024","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2024-02-02"}]